Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | FABP7 | O15540 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18040194 | 0.84 | CYP1A2 (0.33) | CYP1A2TSHRCA1CA2FABP7 | |
| SCHEMBL16933080 | 0.78 | CYP1A2 (0.37) | CYP1A2TSHRKMT2ACA1CA2 | |
| SCHEMBL1198343 | 0.78 | CYP1A2 (0.37) | CYP1A2TSHRKMT2ACA1CA2 | |
| SCHEMBL23525152 | 0.78 | CYP1A2 (0.37) | CYP1A2TSHRKMT2ACA1CA2 | |
| SCHEMBL17505605 | 0.76 | HTR2A (0.37) | CYP1A2TSHRKMT2ACA1CA2 | |
| SCHEMBL17505607 | 0.76 | HTR2A (0.37) | CYP1A2TSHRKMT2ACA1CA2 | |
| SCHEMBL20538932 | 0.74 | ALOX5 (0.40) | CYP1A2TSHRKMT2AGAAMEN1 | |
| SCHEMBL18740261 | 0.74 | ALOX5 (0.40) | CYP1A2TSHRKMT2AGAAMEN1 | |
| SCHEMBL20971992 | 0.73 | CYP1A2 (0.35) | CYP1A2TSHRKMT2ACA1CA2 | |
| SCHEMBL20971990 | 0.73 | CYP1A2 (0.35) | CYP1A2TSHRKMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193471-A1 | ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323893-A1 | BETA2GPI GENE EXPRESSION INHIBITING NUCLEIC ACID COMPLEX | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193471-A1 | ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE | GALNT2, ST6GAL1, SLC17A5 | CYP1A2 2905/4885TSHR 581/4885KMT2A 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.